Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07388745

ESPB vs SPSIP for Postoperative Analgesia After CABG

A Randomized Trial Comparing Erector Spinae Plane Block Versus Serratus Posterior Superior Intercostal Plane Block for Postoperative Analgesic Efficacy in Patients Undergoing Coronary Artery Bypass Graft Surgery

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
64 (estimated)
Sponsor
Kutahya Health Sciences University · Academic / Other
Sex
All
Age
45 Years – 85 Years
Healthy volunteers
Not accepted

Summary

This prospective, randomized, active-controlled, double-blind, parallel-group study compares the postoperative analgesic efficacy and safety of ultrasound-guided bilateral Erector Spinae Plane Block (ESPB) versus bilateral Serratus Posterior Superior Intercostal Plane Block (SPSIPB) in adult patients (45-85 years, ASA I-III) undergoing elective coronary artery bypass graft surgery. The primary outcome is postoperative pain intensity assessed by Numeric Rating Scale (NRS) at 2, 4, 8, 16, 24, and 48 hours after surgery. Secondary outcomes include intraoperative fentanyl/remifentanil consumption, postoperative morphine consumption, patient-controlled analgesia (PCA) demand/delivery parameters (if PCA is used), need for rescue analgesics, extubation and mobilization times, peak inspiratory flow measured by incentive spirometry at predefined time points, ICU and hospital length of stay, recovery quality (QoR-15 at 0, 24, and 48 hours), mortality, and block-related adverse events.

Conditions

Interventions

TypeNameDescription
PROCEDUREUltrasound-guided Erector Spinae Plane Block (ESPB)Bilateral ultrasound-guided ESPB performed preoperatively under sedation at the T4-T5 transverse process level using 20 mL of 0.25% bupivacaine per side (total 40 mL).
PROCEDUREUltrasound-guided Serratus Posterior Superior Intercostal Plane Block (SPSIPB)Bilateral ultrasound-guided SPSIPB performed preoperatively under sedation at the 2nd-3rd intercostal space using 20 mL of 0.25% bupivacaine per side (total 40 mL).

Timeline

Start date
2026-03-01
Primary completion
2026-06-30
Completion
2026-08-31
First posted
2026-02-05
Last updated
2026-02-05

Source: ClinicalTrials.gov record NCT07388745. Inclusion in this directory is not an endorsement.